Comparative Effectiveness of Statin Therapy in Chronic Kidney Disease and Acute Myocardial Infarction: A Retrospective Cohort Study
Smith, David H. ; Johnson, Eric S. ; Boudreau, Denise M. ; Cassidy-Bushrow, Andrea E. ; Fortmann, Stephen P. ; Greenlee, Robert T. ; Gurwitz, Jerry H. ; Magid, David ; McNeal, Catherine J. ; Reynolds, Kristi ... show 9 more
Citations
Authors
Johnson, Eric S.
Boudreau, Denise M.
Cassidy-Bushrow, Andrea E.
Fortmann, Stephen P.
Greenlee, Robert T.
Gurwitz, Jerry H.
Magid, David
McNeal, Catherine J.
Reynolds, Kristi
Steinhubl, Steven R.
Thorp, Micah
Tom, Jeffrey O.
Vupputuri, Suma
VanWormer, Jeffrey J.
Weinstein, Jessica
Yang, Xiuhai
Go, Alan S.
Sidney, Stephen
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Publication Date
Keywords
Aged
Aged, 80 and over
Comparative Effectiveness Research
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Kaplan-Meier Estimate
Male
Middle Aged
Myocardial Infarction
Propensity Score
Proportional Hazards Models
Renal Insufficiency, Chronic
Retrospective Studies
Treatment Outcome
Chronic kidney disease
Comparative effectiveness
Statins
eGFR
Cardiovascular Diseases
Female Urogenital Diseases and Pregnancy Complications
Geriatrics
Hepatology
Male Urogenital Diseases
Subject Area
Embargo Expiration Date
Link to Full Text
Abstract
BACKGROUND: Whether there is a kidney function threshold to statin effectiveness in patients with acute myocardial infarction is poorly understood. Our study sought to help fill this gap in clinical knowledge.
METHODS: We undertook a new-user cohort study of the effectiveness of statin therapy by level of estimated glomerular filtration rate (eGFR) in adults who were hospitalized for myocardial infarction between 2000 and 2008. Data came from the Cardiovascular Research Network. The primary clinical outcomes were 1-year all-cause mortality and cardiovascular hospitalizations, with adverse outcomes of myopathy and development of diabetes mellitus. We calculated incidence rates, the number needed to treat, and used Cox proportional hazards regression with propensity score matching and adjustment to control for confounding, with testing for variation of effect by level of kidney function.
RESULTS: Compared with statin non-initiators (n = 5583), statin initiators (n = 5597) had a lower propensity score-adjusted risk for death (hazard ratio 0.79; 95% confidence interval [CI], 0.71-0.88) and cardiovascular hospitalizations (hazard ratio 0.90; 95% CI, 0.82-1.00). We found little evidence of variation in effect by level of eGFR (P = .86 for death; P = .77 for cardiovascular hospitalization). Adverse outcomes were similar for statin initiators and statin non-initiators. The number needed to treat to prevent 1 additional death over 1 year of follow-up ranged from 15 (95% CI, 11-28) for eGFR < 30 mL/min/1.73 m(2) requiring statin treatment over 2 years to prevent 1 additional death, to 67 (95% CI, 49-118) for patients with eGFR > 90 mL/min/1.73 m(2).
CONCLUSIONS: Our findings suggest that there is potential for important public health gains by increasing the routine use of statin therapy for patients with lower levels of kidney function.
Source
Am J Med. 2015 Nov;128(11):1252.e1-1252.e11. doi: 10.1016/j.amjmed.2015.06.030. Epub 2015 Jul 11. Link to article on publisher's site